Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells

Research output: Contribution to journalArticlepeer-review

Abstract

Fas ligand (FasL/CD95L) is a member of the tumour necrosis factor superfamily that triggers apoptosis following crosslinking of the Fas receptor. Despite studies strongly implicating tumour-expressed FasL as a major inhibitor of the anti-tumour immune response, little is known about the mechanisms that regulate FasL expression in tumours. In this study, we show that the cyclooxygenase (COX) signalling pathway, and in particular prostaglandin E 2 (PGE2), plays a role in the upregulation of FasL expression in colon cancer. Suppression of either COX-2 or COX-1 by RNA interference in HCA-7 and HT29 colon tumour cells reduced FasL expression at both the mRNA and protein level. Conversely, stimulation with PGE2 increased FasL expression and these cells showed increased cytotoxicity against Fas-sensitive Jurkat T cells. Prostaglandin E2-induced FasL expression was mediated by signalling via the EP1 receptor. Moreover, immunohistochemical analysis using serial sections of human colon adenocarcinomas revealed a strong positive correlation between COX-2 and FasL (r=0.722; P<0.0001) expression, and between EP1 receptor and FasL (r=0.740; P<0.0001) expression, in the tumour cells. Thus, these findings indicate that PGE2 positively regulates FasL expression in colon tumour cells, adding another pro-neoplastic activity to PGE2.

Original languageEnglish
Pages (from-to)502-512
Number of pages11
JournalBritish Journal of Cancer
Volume99
Issue number3
DOIs
Publication statusPublished - 5 Aug 2008

Keywords

  • Fas ligand
  • Prostaglandin E
  • Regulation
  • Tumour immune evasion

Fingerprint

Dive into the research topics of 'Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells'. Together they form a unique fingerprint.

Cite this